Jasbir Seehra - Sep 3, 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Keith Regnante, Attorney-in-Fact
Stock symbol: KROS
Transactions as of: Sep 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/5/2025, 04:10 PM
Previous filing: Apr 7, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Seehra Jasbir	CHIEF EXECUTIVE OFFICER, Director	C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON	/s/ Keith Regnante, Attorney-in-Fact	2025-09-05	0001732369

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Award	$0	+90.5K	+29.94%	$0.00	393K	Sep 3, 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 25% of the RSUs shall vest on each of February 18, 2026, February 18, 2027, February 18, 2028 and February 18, 2029, in each case, subject to the Reporting Person continuing to provide service through each such date.